Payment overview · 2025
General Payments
$344.30
36 reported records · 8 companies
Healthcare provider profile · identity verified
Larry Keller, DO
Allopathic & Osteopathic Physicians|Internal Medicine · FLOURTOWN, PA · NPI 1528064094
Verified facts
What the public records show
CMS Open Payments records show Larry Keller, DO received $344.30 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 58.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.41 | 58.8% | 29 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.55 | 9.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.97 | 7.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.14 | 6.4% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $19.19 | 5.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.80 | 4.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.47 | 4.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.77 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $344.30 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $98.62 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $95.58 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.32 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.55 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1145 | 211 |
| Amlodipine Besylate | Amlodipine Besylate | 967 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 698 | 130 |
| Gabapentin | Gabapentin | 576 | 91 |
| Furosemide | Furosemide | 498 | 79 |
| Eliquis | Apixaban | 484 | 62 |
| Losartan Potassium | Losartan Potassium | 444 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 403 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 401 | 71 |
| Lisinopril | Lisinopril | 399 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 399 | 63 |
| Potassium Chloride | Potassium Chloride | 395 | 57 |
| Simvastatin | Simvastatin | 367 | 58 |
| Lorazepam | Lorazepam | 321 | 75 |
| Sertraline Hcl | Sertraline Hcl | 318 | 53 |
| Metformin Hcl | Metformin Hcl | 301 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 297 | 50 |
| Omeprazole | Omeprazole | 296 | 80 |
| Mirtazapine | Mirtazapine | 280 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 250 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 246 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 236 | 47 |
| Atenolol | Atenolol | 230 | 38 |
| Levetiracetam | Levetiracetam | 228 | 29 |
| Carvedilol | Carvedilol | 205 | 39 |
| Montelukast Sodium | Montelukast Sodium | 203 | 46 |
| Memantine Hcl | Memantine Hcl | 202 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 197 | 32 |
| Donepezil Hcl | Donepezil Hcl | 196 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 194 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 48 |
| Famotidine | Famotidine | 170 | 34 |
| Risperidone | Risperidone | 145 | 12 |
| Trazodone Hcl | Trazodone Hcl | 145 | 35 |
| Allopurinol | Allopurinol | 130 | 27 |
| Xarelto | Rivaroxaban | 130 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 38 |
| Alprazolam | Alprazolam | 129 | 28 |
| Tramadol Hcl | Tramadol Hcl | 128 | 32 |
| Jardiance | Empagliflozin | 124 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 24 |
| Clonazepam | Clonazepam | 115 | 15 |
| Latanoprost | Latanoprost | 115 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 14 |
| Buspirone Hcl | Buspirone Hcl | 103 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 39 |
| Ezetimibe | Ezetimibe | 95 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 95 | 31 |
| Finasteride | Finasteride | 91 | 21 |
| Valsartan | Valsartan | 90 | 17 |
| Metformin Hcl Er | Metformin Hcl | 89 | 21 |
| Bupropion Xl | Bupropion Hcl | 84 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 81 | suppressed |
| Loperamide | Loperamide Hcl | 81 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 63 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 18 |
| Alendronate Sodium | Alendronate Sodium | 79 | 14 |
| Nifedipine Er | Nifedipine | 78 | 20 |
| Methylprednisolone | Methylprednisolone | 74 | 46 |
| Aripiprazole | Aripiprazole | 73 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | suppressed |
| Trulicity | Dulaglutide | 71 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 69 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 11 |
| Cephalexin | Cephalexin | 59 | 40 |
| Myrbetriq | Mirabegron | 59 | suppressed |
| Olanzapine | Olanzapine | 58 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | suppressed |
| Baclofen | Baclofen | 57 | suppressed |
| Ibuprofen | Ibuprofen | 57 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 33 |
| Pregabalin | Pregabalin | 55 | 11 |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 53 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 34 |
| Methenamine Hippurate | Methenamine Hippurate | 49 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | 11 |
| Glipizide | Glipizide | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 14 |
| Ozempic | Semaglutide | 48 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 15 |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 31 |
| Nortriptyline Hcl | Nortriptyline Hcl | 46 | suppressed |
| Nystatin | Nystatin | 46 | 25 |
| Amoxicillin | Amoxicillin | 44 | 26 |
| Meloxicam | Meloxicam | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 13 |
| Lacosamide | Lacosamide | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 40 | 40 |
| Levofloxacin | Levofloxacin | 40 | 28 |
| Topiramate | Topiramate | 40 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 39 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 27 |
| Midodrine Hcl | Midodrine Hcl | 35 | 12 |
| Prednisone | Prednisone | 35 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 16 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Timolol Maleate | Timolol Maleate | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 29 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Admelog Solostar | Insulin Lispro | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Restasis | Cyclosporine | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 25 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Sulfasalazine | Sulfasalazine | 21 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Alogliptin | Alogliptin Benzoate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Enulose | Lactulose | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Ethosuximide | Ethosuximide | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 18 | 14 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Alphagan P | Brimonidine Tartrate | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Pentasa | Mesalamine | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Norvasc | Amlodipine Besylate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $344.30 · 36 records | ABBVIE INC. | BREZTRI, CAPVAXIVE, GARDASIL 9, JARDIANCE, QULIPTA, REPATHA, SPINRAZA, UBRELVY, VRAYLAR, Veozah, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error